Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The heat shock protein 90–cell division cycle 37 complex is a molecular chaperone system critical for the folding, stabilization, and activation of a broad range of kinases, particularly protein kinases involved in signal transduction and cell cycle regulation[1][2][3][4][5]. Hsp90 is an ATP-dependent chaperone, and Cdc37 acts as a co-chaperone, serving as an adaptor that selectively recruits protein kinase clients to Hsp90[1][2][4][5]. Cdc37 binds both the N-terminal domain of client kinases and the middle domain of Hsp90, stabilizing kinases in a partially unfolded state to enable their subsequent activation and functional maturation in response to Hsp90's ATP cycle[2][3][5]. This complex is essential for the stability and activity of many oncogenic kinases, rendering it a validated therapeutic target, especially in cancer, where its disruption leads to degradation of multiple driver kinases and impaired signaling pathways relevant to tumor growth and survival[1][2]. Inhibitors targeting Hsp90 or the Hsp90–Cdc37 interaction are under investigation for cancer therapy, but clinical development has been limited by toxicity and a broad impact on many cellular proteins[2][5]. The complex also plays roles in other diseases where kinase homeostasis is perturbed, and its activity or substrate spectrum can be monitored through levels or phosphorylation status of client proteins[4][5].
Inhibition of Hsp90 ATPase activity disables client kinase maturation and refolding, leading to proteasomal degradation of oncogenic kinases and impaired signaling - Disruption of Hsp90–Cdc37 interaction, thereby blocking protein kinase client recruitment and stabilization
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heat shock protein 90–cell division cycle 37 complex (Hsp90–Cdc37 complex).